Payment overview · 2025
General Payments
$106.65
5 reported records · 4 companies
Healthcare provider profile · identity verified
Steven Argumedo, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SAN ANTONIO, TX · NPI 1780864751
Verified facts
What the public records show
CMS Open Payments records show Steven Argumedo, MD received $106.65 in general payments during 2025 across 5 reported records.
Abbott Laboratories accounted for 45.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $48.34 | 45.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.92 | 20.6% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $19.44 | 18.2% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $16.95 | 15.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $106.65 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $48.34 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $21.92 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $16.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Montelukast Sodium | Montelukast Sodium | 941 | 271 |
| Atorvastatin Calcium | Atorvastatin Calcium | 503 | 168 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 457 | 126 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 437 | 136 |
| Amlodipine Besylate | Amlodipine Besylate | 418 | 132 |
| Losartan Potassium | Losartan Potassium | 409 | 120 |
| Lisinopril | Lisinopril | 389 | 124 |
| Fluticasone Propionate | Fluticasone Propionate | 361 | 159 |
| Levothyroxine Sodium | Levothyroxine Sodium | 318 | 100 |
| Allopurinol | Allopurinol | 272 | 82 |
| Metformin Hcl | Metformin Hcl | 230 | 82 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 201 | 79 |
| Ozempic | Semaglutide | 189 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 184 | 64 |
| Pravastatin Sodium | Pravastatin Sodium | 182 | 56 |
| Jardiance | Empagliflozin | 166 | 53 |
| Trulicity | Dulaglutide | 165 | 46 |
| Azelastine Hcl | Azelastine Hcl | 157 | 80 |
| Escitalopram Oxalate | Escitalopram Oxalate | 155 | 43 |
| Gabapentin | Gabapentin | 154 | 51 |
| Omeprazole | Omeprazole | 151 | 50 |
| Sertraline Hcl | Sertraline Hcl | 148 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 147 | 46 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 141 | 44 |
| Carvedilol | Carvedilol | 126 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 118 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 114 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 111 | 30 |
| Pioglitazone Hcl | Pioglitazone Hcl | 110 | 40 |
| Prednisone | Prednisone | 103 | 72 |
| Furosemide | Furosemide | 101 | 35 |
| Alendronate Sodium | Alendronate Sodium | 96 | 31 |
| Mounjaro | Tirzepatide | 94 | 25 |
| Topiramate | Topiramate | 94 | 25 |
| Januvia | Sitagliptin Phosphate | 91 | 30 |
| Finasteride | Finasteride | 85 | 24 |
| Bumetanide | Bumetanide | 82 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 81 | 21 |
| Nifedipine Er | Nifedipine | 81 | 30 |
| Mirtazapine | Mirtazapine | 78 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 77 | 26 |
| Famotidine | Famotidine | 74 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 66 | 16 |
| Metformin Hcl Er | Metformin Hcl | 65 | 20 |
| Valsartan | Valsartan | 65 | 19 |
| Simvastatin | Simvastatin | 60 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 58 | 13 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 57 | 15 |
| Pregabalin | Pregabalin | 53 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 51 | 34 |
| Citalopram Hbr | Citalopram Hydrobromide | 51 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 13 |
| Linzess | Linaclotide | 46 | 16 |
| Aripiprazole | Aripiprazole | 45 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 45 | 14 |
| Farxiga | Dapagliflozin Propanediol | 45 | 11 |
| Myrbetriq | Mirabegron | 41 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 41 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | 13 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 40 | suppressed |
| Eliquis | Apixaban | 39 | 12 |
| Levofloxacin | Levofloxacin | 39 | 26 |
| Potassium Chloride | Potassium Chloride | 38 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 36 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 35 | suppressed |
| Nystatin | Nystatin | 34 | 23 |
| Naproxen | Naproxen | 33 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Spironolactone | Spironolactone | 32 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 32 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 31 | suppressed |
| Ibuprofen | Ibuprofen | 31 | 12 |
| Creon | Lipase/Protease/Amylase | 30 | suppressed |
| Fluconazole | Fluconazole | 30 | 25 |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Ketoconazole | Ketoconazole | 25 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 24 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Metronidazole | Metronidazole | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 18 |
| Baclofen | Baclofen | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Meloxicam | Meloxicam | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 14 |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 13 | 13 |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Embrace Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 11 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
| Victoza 3-Pak | Liraglutide | 11 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $106.65 · 5 records | Abbott Laboratories | FREESTYLE LIBRE 3, Omnipod, Senza, The Cologuard Plus Collection Kit | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error